-
Las Vegas Sands Corp. (NYSE: LVS) shares gained 1.6
percent to reach a new 52-week high of $57.45. Argus Research upgraded Las Vegas Sands from Hold to Buy.
-
Vitae Pharmaceuticals Inc (NASDAQ: VTAE) shares
climbed 158 percent to touch a new 52-week high of $20.89. Allergan plc (NYSE: AGN) and Vitae Pharmaceuticals reached an agreement by which the former would buy
the latter for $21.00 a share in cash.
-
Exelixis, Inc. (NASDAQ: EXEL) shares touched a
new 52-week high of $13.11 after the company disclosed that the EC has approved CABOMETYX tablets for the treatment of advanced
renal cell carcinoma following VEGF-targeted therapy.
-
Seattle Genetics, Inc. (NASDAQ: SGEN) shares rose
4.5 percent to touch a new 52-week high of $54.01. Seattle Genetics shares have climbed 10.49 percent over the past 52 weeks,
while the S&P 500 index has increased 8.91 percent in the same period.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.